Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
IPO Year: 2016
Exchange: NASDAQ
Website: tactilemedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2025 | $14.00 | Overweight → Neutral | Piper Sandler |
| 2/19/2025 | $23.00 → $18.00 | Buy → Neutral | B. Riley Securities |
| 11/5/2024 | Outperform → Perform | Oppenheimer | |
| 11/5/2024 | Buy → Neutral | BTIG Research | |
| 9/26/2024 | $23.00 | Buy | B. Riley Securities |
SCHEDULE 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
SCHEDULE 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SD - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
S-8 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
DEFA14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler downgraded Tactile Systems from Overweight to Neutral and set a new price target of $14.00
B. Riley Securities downgraded Tactile Systems from Buy to Neutral and set a new price target of $18.00 from $23.00 previously
Oppenheimer downgraded Tactile Systems from Outperform to Perform
BTIG Research downgraded Tactile Systems from Buy to Neutral
B. Riley Securities initiated coverage of Tactile Systems with a rating of Buy and set a new price target of $23.00
BTIG Research reiterated coverage of Tactile Systems Technology with a rating of In-Line and set a new price target of $60.00 from $51.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
Fastest customizable press release news feed in the world
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 millionGross margin of 75% versus 74% in Q2 2024Net income of $3.2 million versus $4.3 million in Q2 2024Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treatin
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided o
MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company's Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema. "Current modalities for managing head and neck cancer-related lymphedema include therapist guided lymphedema treatment and lifelong home-based self-car
MINNEAPOLIS, May 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will be participating in two upcoming investor conferences. Tactile Medical is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 3:20 p.m. CST and at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 2:35 p.m. EST. Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 3:20 p.m. CST Event: Jefferies Global Healt
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the
MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be accessible under the "Events & Webcasts" section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the w
MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 10% year-over-year to $85.6 millionGross margin of 75% versus 72% in Q4 2023Net income of $9.7 million versus $8.2 million in Q4 2023Adjusted EBITDA of $16.2 million versus $15.4 million in Q4 2023Expanded launch of Nimbl to include patients with lower extremity lymphedemaAppointed Laura King to Board of
MINNEAPOLIS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2024 financial results will be released after the market closes on Tuesday, February 18, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 18, 2025, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13751026. A live webcast of the call
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl's expanded availability to include lower extremity conditions ("phlebolymphedema") follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema. "On the heels of Nimbl's launch for patients with
Live Leadership Updates
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE
PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea
MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s
MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who will be resigning from the Company, effective July 28, 2023. "Sherri is a strategic leader with over 25 years of experience in the healthcare industry and a successful history of developing and leading high-performance teams at scale," said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. "Sherri brings ex
MINNEAPOLIS, March 14, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Elaine Birkemeyer to the position of Chief Financial Officer, effective March 20, 2023. Ms. Birkemeyer will succeed Brent Moen, who is retiring. "Elaine is a dynamic and purpose-driven leader with over 25 years of experience in finance, accounting, and business strategy, including extensive senior leadership experience at multiple Fortune 500 companies, leading large divisions within the healthcare, consumer and retail industries," said Da
MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Brent Moen has communicated his intention to retire as Chief Financial Officer in 2023. "I would like to thank Brent for his important contributions to our organization during his tenure," said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. "Brent was instrumental in helping Tactile Medical to navigate the headwinds created by the COVID-19 pandemic, to successfully complete and integrate the acquisition of our AffloVest airway clearan
Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI. COLUMBUS, Ohio, April 13, 2022 /PRNewswire/ -- Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer. He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.
MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will
PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa
MINNEAPOLIS, May 03, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today reported financial results for the first quarter ended March 31, 2021. First Quarter 2021 Summary: Total revenue decreased 2% year-over-year, to $42.8 million, compared to $43.7 million in first quarter 2020.Operating loss of $4.1 million, compared to operating loss of $4.5 million in first quarter 2020.Net loss of $2.3 million, compared to net loss of $1.3 million in first quarter 2020.Adjusted EBITDA loss of $7,000, compared to Adjusted EBITDA loss of $0.5
This live feed shows all institutional transactions in real time.
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
Live finance-specific insights
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 millionGross margin of 75% versus 74% in Q2 2024Net income of $3.2 million versus $4.3 million in Q2 2024Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treatin
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided o
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the
MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 10% year-over-year to $85.6 millionGross margin of 75% versus 72% in Q4 2023Net income of $9.7 million versus $8.2 million in Q4 2023Adjusted EBITDA of $16.2 million versus $15.4 million in Q4 2023Expanded launch of Nimbl to include patients with lower extremity lymphedemaAppointed Laura King to Board of
MINNEAPOLIS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2024 financial results will be released after the market closes on Tuesday, February 18, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 18, 2025, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13751026. A live webcast of the call
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023Adjusted EBITDA of $10.7 million versus $7.7 million in Q3
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13748661. A live webcast of the call will also be provide
MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Total revenue increased 7% year-over-year to $73.2 million Lymphedema product revenue increased 8% year-over-yearAirway clearance product revenue increased 2% year-over-year Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 mill
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2024 financial results will be released after the market closes on Monday, August 5, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 5, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided o